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Abstract KRAS mutation testing is mandatory before pre-
scribing anti-epidermal growth factor monoclonal antibodies
in the treatment of advanced colorectal cancer. We describe the
performance of a TaqMelt polymerase chain reaction (PCR)
assay—the cobas® KRAS Mutation Test—designed to detect
19 mutations in codons 12, 13, and 61. The limit of detection
was determined using DNA blends from cell lines, plasmids,
and formalin-fixed paraffin-embedded tissue specimens. Assay
performance was compared to Sanger sequencing using a panel
of188specimens.Discordantspecimensweresubjectedtonext
generation pyrosequencing (454). Assay repeatability was
assessed using a panel of six specimens. A >95% correct
mutation call rate was obtained in all specimen types with
~5% mutant alleles at DNA inputs of 0.8–6.3 ng per PCR
reaction; 100% detection rate was observed at the recommen-
ded DNA input of 50 ng. The positive percent agreement with
Sanger was 97.5% (79/81)for codons 12/13and85.7% (6/7) for
codon 61. Negative percent agreement was 94.4% (101/107) for
codon 12/13 and 99.4% (180/181) for codon 61. Nine of 10
discordant specimens yielded 454 results consistent with the
cobas®results.With repeatedtesting,theassayshowed acorrect
call rate of 100% (192/192) for all operators, instruments,
reagent lots, and days tested. The cobas® test detects KRAS
mutations in codons 12, 13, and 61 at a limit of detection of
<5%. The PCR assay was more sensitive and specific than
Sanger sequencing, and performance was highly reproducible.
Test performance was not influenced by various endogenous
interfering substances or common gut microbes.
Keywords KRASmutations.Moleculardiagnostics.
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Background
Mutations in the KRAS gene that lead to its constitutive
activationhavebeenidentifiedin24–43% ofcolorectalcancer
(CRC) tumors and are common in other tumor types such as
pancreatic, lung, thyroid, and myeloid leukemia [1–3]. These
gain of function mutations lead to epidermal growth factor
receptor (EGFR)-independent activation of intracellular sig-
naling pathways, resulting in tumor cell proliferation, protec-
tion against apoptosis, increased invasion and metastasis, and
activation oftumor-inducedangiogenesis[4].Thepresenceof
activating mutations has been shown in randomized clinical
trials to play a crucial role in predicting non-responsiveness in
patients with advanced CRC who receive the anti-EGFR
monoclonal antibodies cetuximab and panitumumab [5–9].
The majority of activating mutations in CRC tumors occur
in codons 12 (~82%) and 13 (~17%) of exon 2 of the KRAS
gene;however,mutationsincodon61(exon3)havealsobeen
described[10].Codon61mutationshavebeenshowntoresult
in constitutive activation of KRAS just as codon 12 and 13
mutations do [11, 12], and limited clinical data indicate that
codon 61 mutations may predict non-response to anti-EGFR
monoclonal antibody therapy [13–15].
The high level evidence supporting the clinical utility of
KRAS mutation status in predicting response to anti-EGFR
monoclonal antibodies has led to specific requirements for
KRAS mutation testing by European and US regulatory
authorities [16, 17]. Major oncology guidelines, including
those of the European Society for Medical Oncology [18]
and the American Society of Clinical Oncology [19], have
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DOI 10.1007/s00428-011-1180-0all embraced the recommendation that these antibodies be
restricted to patients with KRAS wild-type colorectal cancers.
Bi-directional Sanger sequencing, which theoretically
can identify all possible mutations in an exon, has been a
common reference method for detecting somatic mutations
in tumor specimens. However, Sanger sequencing suffers
from limited sensitivity for low-level mutant alleles, par-
ticularly in formalin-fixed paraffin-embedded tissue (FFPET)
specimens, and has a slow turnaround time [20]. A number of
other KRAS mutation detection methods, including allele-
specific PCR assays, high-resolution melting analysis, and
pyrosequencing, have been developed [21, 22]. These
other methods have been reported to have varying levels
of sensitivity and specificity for detecting KRAS mutations
andthere iscurrentlynouniformstandardforKRASmutation
testing.
There is a clear need for a well-validated, robust, and
reproduciblemethod.TheEuropeanUnioninvitroDiagnostic
(IVD) Medical Device Directive 98/79/EC requires that IVDs
“achieve the performance…stated by the manufacturer” for a
variety of test attributes such as limits of detection, analytical
sensitivity and specificity, reproducibility/repeatability, and
potential interfering and cross-reacting substances. Aligning
with the European Union IVD directives and optimizing the
analytical performance of a mutation assay requires thorough
validation testing on different specimen types (including the
intendeduseofFFPETspecimens)aswellasacomprehensive
understanding of the impact of specimen attributes, such as
the tumor content, the levels of amplifiable DNA, necrosis,
and the influence of endogenous and exogenous interfering
substances.
We set out to design a robust, accurate molecular diag-
nostic test to identify patients who have CRC tumors with
somatic mutations in codons 12 and 13 of exon 2 or 61 of
exon 3 of the KRAS gene and who are therefore unlikely to
benefit from therapy with anti-EGFR monoclonal anti-
bodies. The cobas® KRAS Mutation Test (Roche Molecular
Systems, Branchburg, NJ, USA), for use with the cobas®
4800 System v2.0 is a TaqMelt™ real-time PCR test
intended to detect 19 mutations in codons 12 and 13 of
exon 2 and 61 of exon 3 of the KRAS gene using DNA
derived from FFPET from human CRC tumors. In this report,
we present data on the analytic performance of the cobas®
test.
Material and methods
Materials
FFPETspecimensfromCRCtumorswerepurchasedfromUS
commercialvendors:DiscoveryLifeSciences,Inc.(LosOsos,
CA, USA); BioServe (Beltsville, MD, USA); ProteoGenex
(Culver City, CA, USA); CureLine, Inc. (San Francisco, CA,
USA); and Indivumed, Inc. (Kensington, MD, USA). The
FFPET specimens from vendors were from CRC stages I to
IV with a majority from stages II and III. Estimated tumor
content ranged from 25% to 80%.
Cobas® KRAS mutation test
The cobas® KRAS Mutation Test kit (cobas® test) is a Taq-
Melt™-basedPCRassay(Fig.1).Thetestingprocessconsists
of two main steps: manual specimen preparation to obtain
genomic DNA from FFPETand PCR amplification and detec-
tion of target DNA using complementary primer pairs and two
oligonucleotide probes labeled with different fluorescent dyes.
The PCR primers are designed to amplify defined sections of
exons 2 and 3 of the KRAS gene, and fluorescently labeled
oligonucleotide probes detect mutations in codons 12, 13, and
61, which fall within these exons.
DNA extraction: DNAisextractedfromasingle,deparaffi-
nized5μmsectionofFFPETfollowingthestandardprocedure
described in the cobas® DNA Sample PreparationKit package
insert. A deparaffinized specimen is lysed by incubation at an
elevated temperature with a protease and chaotropic lysis/
binding buffer that releases nucleic acid and protects the
released genomic DNA from DNases. Subsequently, isopro-
panol is added to the lysis mixture that is then centrifuged
through a column with a glass fiber filter. Unbound substan-
ces, such as salts, proteins, and other cellular impurities, are
removed by centrifugation. The adsorbed nucleic acids are
washedandthenelutedwithanaqueoussolution.The amount
of genomic DNA is spectrometrically determined and adjust-
ed to a fixed concentration of 2 ng/μL.
PCR amplification and detection: The target DNA is
amplified and detected on the cobas® 4800 system, which
measures the fluorescence generated by specific PCR prod-
ucts, using the amplification and detection reagents provid-
ed in the cobas® KRAS Mutation Test kit (Fig. 1). Mutation
detection is achieved by melting curve analysis, using an
automated result interpretation software package (KRAS
Assay Specific Analysis Package v1.0). Based on melting
temperatures and peak heights for mutants and wild types,
mutation status of each specimen was determined. A mutant
control, a negative control, and a calibrator are included in
each run to confirm the validity of the run. Amplification,
detection, quality control analysis, and result interpretation
are automated on the system; raw data and melting curves
are not reported. The DNA isolation, amplification/detection,
and resultreporting can beperformed inlessthan8 h.The test
kit is configured such that users running a minimum of three
specimens canachieve thefullnumberof24reportableresults
per kit; as many as 45 specimens can be processed in a single
test run.
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DNA prepared from FFPETspecimens using the same extrac-
tion method as described for the cobas® test were sequenced
by 2X bi-directional Sanger sequencing by a Clinical Labora-
tory Improvement Amendments (CLIA)-certified laboratory
(SeqWright, Houston, TX) using a validated protocol.
454 quantitative massively parallel pyrosequencing
Specimens which gave discordant cobas® test and
Sanger test results were retested using a quantitative
massively parallel pyrosequencing method (454 GS
Titanium, 454 Life Sciences, Branford, CT) by a
CLIA-certified laboratory (SeqWright, Houston,TX)using
a validated protocol. Additionally, a randomly selected subset
of specimens with concordant cobas® test and Sanger results
were tested by 454 sequencing to confirm the accuracy of
mutation status. The validated limit of detection for the 454
KRAS protocol was 1%.
Limit of detection
The limit of detection (LOD) of the cobas® test was evalu-
ated for one predominant mutation in codon 12 (GAT),
codon 13 (GAC), and codon 61 (CAC) of the KRAS gene
with ~5% mutation. Testing on 24–72 replicates per panel
memberatdifferentlevelsofDNA input was conductedusing
the following specimen types:
& FFPET specimens,
& DNA extracted from CRC FFPET mutant and wild-type
specimens,
& DNA extracted and blended from two CRC mutant and
wild-type cell lines for codons 12 and 13, and
& DNA from one mutant plasmid for codon 61 blended
with wild-type KRAS cell line DNA.
Testing was performed using three lots of the cobas® test
kit and one lot of the cobas® DNA Sample Preparation Kit.
DNA extracted from each specimen type was then serially
diluted to DNA input levels ranging from 50.0 to 0.4 ng per
reaction well, in order to simulate varying degrees of DNA
degradation that may occur with formalin fixation. 454
sequencing was used to assess percent mutant alleles for
DNA extracted from each specimen type. Sensitivity was
determined based on a correct mutation call rate of ≥95%
and by Probit analysis.
In a separate analysis, the LOD was evaluated for 16
additional KRAS mutation genotypes. Due to the lack of
naturally occurring specimens with ~5% mutant alleles,
Fig. 1 Assay workflow. Two 5-μm sections are prepared from each
FFPET specimen—one section is used for H&E staining to assess
tumor content and the other section is used for DNA isolation. If the
tumor content is greater than 10%, which all of the specimens for the
studies in this report were, then no macro-dissection is required.
Genomic DNA is isolated using the cobas® DNA Sample Preparation
Kit and two 25-μL aliquots (one aliquot for codon 12/13 of exon 2 and
the other aliquot for codon 61 of exon 3) of the resulting extract that is
adjusted to 2 ng/μL of DNA are amplified using cobas z 480 analyzer.
Change in fluorescence during melting steps is automatically analyzed
for melting temperatures and peak heights for mutants and wild types
to determine mutation status of each specimen
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assessed by 454 sequencing) were prepared including:
& Five FFPET blends representing five KRAS codon 12
mutations,
& Five blends (four plasmid and one FFPET) representing
five KRAS codon 13 mutations, and
& Six blends (two plasmid and four FFPET) representing
six KRAS codon 61 mutations.
Before cobas® testing, the mutation status and mutation
percentage of the specimens were verified by 2X bi-directional
Sanger sequencing and 454 sequencing, respectively.
Analytic sensitivity and specificity—methods correlation
with Sanger sequencing
The analytic performance of the cobas® test was evaluated
by comparing two lots of the cobas® KRAS test to 2X bi-
directional Sanger Sequencing using 188 vendor-purchased
CRC FFPET specimens. Each cobas® test reagent lot was
paired with a separate lot of the cobas® DNA Sample Prepa-
ration Kit. Specimens were tested in a blinded fashion for the
presence of codon 12, 13, and 61 mutations. Positive and
negative percent agreements between the cobas® test and
Sanger test results were determined. Discrepant analysis was
performed by testing specimens with discordant cobas® test
and Sanger results with 454 sequencing for resolution. In
addition, 50 randomly selected specimens with concor-
dant Sanger and cobas® test results were tested by 454
sequencing in order to provide further verification of the
correct call rate.
Repeatability
The repeatability of the cobas® test was evaluated across
different reagent lots, days, operators, and instruments with
six FFPET CRC specimens, two KRAS wild-type, and four
KRAS mutation positive. The materials used in the repeatability
testing are:
& One cobas® DNA Sample Preparation Kit lot,
& Two cobas® KRAS Mutation Test Kit lots,
& Two operators, and
& Four cobas® 4800 System v.2.0.
Each operator performed one run per reagent lot per day
for 4 days for a total of 16 runs with two replicates of each
of the six specimens.
Interfering endogenous substances
The effects of endogenous substances, hemoglobin and tri-
glycerides, on the performance of the cobas® test were
investigated in 10 CRC FFPET specimens. The specimens
were selected for mutation status based on Sanger and/or
454 sequencing. Five specimens were KRAS mutation posi-
tive and five were wild type. Four 5-μm sections were
extracted for each specimen, one each in the following:
& Tissue Lysis Buffer + Proteinase K (TLB/PK) (control),
& TLB/PK + saline (solvent control),
& TLB/PK + 2 g/L hemoglobin (CLSI-recommended test
concentrations), and
& TLB/PK + 37 mM triglycerides.
Hemoglobin and triglycerides were added during the lysis
step of DNA extraction and were not subjected to deparaffi-
nization. All DNA extracts were tested for interference of
mutation detection using the cobas® test.
Interference by common colon-related microorganisms
The effects of colon-related microorganisms on the perfor-
mance of the cobas® test were investigated in 10 FFPET
CRC specimens. The specimens were selected for mutation
status basedon Sangerand/or454 sequencing. Fivespecimens
were KRAS mutation positive and five were wild type.
Approximately one million colony-forming units of Bacter-
oides caccae,Prevotellaintermedia,an dEscherichia coliwas
added during the lysis step of DNA extraction. Phosphate-
buffered saline and blank controlswere also tested. One 5-μm
section of each specimen was extracted and all DNA extracts
were tested for interference of mutation detection using the
cobas® test.
Cross-reactivity
The cross-reactivity of the cobas® test with a panel of KRAS
silent mutations and KRAS homolog plasmids was assessed.
Plasmids containing one each of three silent codon 12 muta-
tions and three silent codon 13 mutations were prepared in a
background of wild-type cell line DNA and tested in the
presenceandabsenceof5%KRASmutantDNA.Additionally,
cross-reactivity and interference of the cobas® test were
assessed with highly homologous RAS gene sequences present
in the human genome (HRAS, NRAS, and pseudogene
KRAS1P). Six plasmids (KRAS codon 12/13 pseudogene,
codon 61 pseudogene, NRAS exon 2, NRAS exon 3, HRAS
exon 2, and HRAS exon 3) were blended with KRAS wild-
type DNA (K562 cell line DNA) and tested in the presence and
absence of 5% KRAS mutant DNA. Each blend was tested in
triplicate.
Necrosis
Theimpactoftissuenecrosisontheperformanceofthecobas®
test was evaluated in duplicate in 20 FFPET CRC specimens
with varying percentages of necrotic tissue (5–70%) as
144 Virchows Arch (2012) 460:141–149assessed by an external pathologist. Mutation status was veri-
fied by Sanger sequencing. The FFPETspecimens used were:
& Ten wild-type specimens with 30–70% necrotic tissue,
& FiveKRAScodon12mutantswith30–45%necrotictissue,
& Four KRAS codon 13 mutants with 15–50% necrotic
tissue, and
& One KRAS codon 61 mutant with 5% necrotic tissue.
Results
Limit of detection
For the LOD analysis for the three predominant mutations in
codons 12, 13, and 61, ≥95% correct mutation call rates were
obtained across all specimen types with approximately 5%
mutant alleles (as assessed by 454) at a DNA input of 0.8–
6.3 ng per reaction well (Table 1). A 100% correct mutation
call rate for the remaining 16 mutations in codons 12, 13, and
61 for all specimens was obtained at the recommended DNA
input of 50 ng per reaction well (Table 2).
Methods correlation
The analytic performance of the cobas® test and 2X bi-
directional Sanger sequencing was compared with a total of
188 FFPET vendor-purchased specimens using two different
cobas®testreagentlots.Concordancebetweenthecobas®test
and Sanger sequencing for each lot was 97.5% positive per-
cent agreement (PPA) and 94.4% negative percent agreement
(NPA) for codon 12/13 and 85.7% PPA and 99.4% NPA for
codon61(Table3,columns AandB).Eightdiscordantresults
for codon 12/13 and two for codon 61 were subjected to 454
sequencing. Six specimens were reported mutation-detected
codon 12/13 by the cobas® test and mutation not detected
by Sanger. 454 results agreed with the cobas® test in five
of the six cases. The other two specimens were reported
mutation not detected codon 12/13 by the cobas® test and
mutation detected by Sanger. 454 agreed with the cobas®
Table 1 Summary of limit of detection (LOD) results for the three
most predominant KRAS mutations
KRAS
mutation
Specimen
type and ID
Mutation
(%)
Lowest DNA input
(ng/PCR) for a
mutation rate ≥95%
Codon 12
(exon 2)
GGT>GAT
FFPET specimen 4.3 3.1
FFPET blend #1 4.2 3.1
FFPET blend #2 4.7 3.1
Cell line blend 5.3 0.8
Codon 13
(exon 2)
GGC>GAC
FFPET blend #1 5.0 3.1
FFPET blend #2 4.6 1.6
FFPET blend #3 7.2 1.6
Cell line blend 4.9 1.6
Codon 61
(exon 3)
CAA>CAC
FFPET blend #1 4.4 3.1
FFPET blend #2 5.5 3.1
FFPET blend #3 3.8 6.3
Plasmid blend 5.8 6.3
FFPET formalin-fixed paraffin-embedded tissue
Table 2 Limit of detection
(LOD) results for the remaining
16 KRAS mutations at ~5%
at recommended DNA input of
50 ng per reaction well
Correct call rate
Sample Codon Mutation Valid
replicates
KRAS mutation
test results (codon)
Correct
mutation calls
Accuracy (%)
1 12 GGT>AGT 24 12/13 24 100
2 12 GGT>CGT 24 12/13 24 100
3 12 GGT>TGT 24 12/13 24 100
4 12 GGT>GCT 24 12/13 24 100
5 12 GGT>GTT 24 12/13 24 100
6 13 GGC>AGC 24 12/13 24 100
7 13 GGC>CGC 24 12/13 24 100
8 13 GGC>TGC 24 12/13 24 100
9 13 GGC>GCC 24 12/13 24 100
10 13 GGC>GTC 24 12/13 24 100
11 61 CAA>AAA 24 61 24 100
12 61 CAA>GAA 24 61 24 100
13 61 CAA>CTA 24 61 24 100
14 61 CAA>CGA 26 61 26 100
15 61 CAA>CCA 24 61 24 100
16 61 CAA>CAT 24 61 24 100
Virchows Arch (2012) 460:141–149 145test in both cases. Therefore, 454 sequencing results
agreed with the cobas® test for seven of the eight dis-
crepant specimens. One unique specimen per lot remained
discordant for codon 12/13 mutation status after 454 se-
quencing. Both discordant specimens displayed low peak
heights in the cobas assay, suggesting the presence of very
low levels of mutant alleles. After discordant resolution
with 454 sequencing, the PPA for codon 12/13 was 100%
and the NPA was 99% (Table 3, column C). 454 sequenc-
ing results of the two discordant specimens for codon 61
agreed with the cobas® test. After discordant resolution
with 454 sequencing, the PPA and the NPA for codon 61
were 100% (Table 3, column D). In addition to the 10
discrepant specimens, 50 specimens with concordant
cobas® test and Sanger sequencing results (26 codon 12/
13 mutations, 6 codon 61 mutations, and 18 mutation not
detected specimens) were subjected to 454 sequencing.
The 454 sequencing results for all 50 concordant specimens
were concordant with the Sanger sequencing and cobas®
KRAS test results.
Repeatability
All 16 repeatability runs were valid. The cobas® test had a
mutation result accuracy of 100% (192/192 replicates) across
all specimens, reagent lots, operators, and instruments com-
bined (Table 4).
Interfering substances
No interference was observed for any of the 10 specimens
tested for potential endogenous interfering substances (he-
moglobin and triglycerides) at Clinical and Laboratory
Standards Institute recommended test concentrations of
2 g/L and 37 mM, respectively. None of the exogenous
colon-related microorganisms tested interfered with the
cobas® test. All five of the KRAS wild-type specimens
spiked with an exogenous substance gave valid results of
“mutation not detected”, while all five KRAS-mutant
specimens spiked with an exogenous substance gave valid
results of “mutation detected” for the correct codon. Both
study controls gave valid and accurate mutation results
(data not shown).
Cross-reactivity
The cobas® test did not cross-react with either KRAS silent
mutations in codons 12/13 or highly homologous RAS gene
sequences. When tested in a wild-type background, all plas-
midblendstestedwitheitherKRASsilentmutationsorKRAS
homologs resulted in “mutation not detected”.W h e nt e s t e di n
a background of 5% KRAS-mutant DNA, all plasmid blends
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146 Virchows Arch (2012) 460:141–149resulted in “mutation detected” for the correct codon (data not
shown).
Necrosis
No interference from necrotic tissue was observed when eval-
uating the performance of the cobas® test. Results for all
specimens were concordant with Sanger and 454 sequencing
results. Necrosis up to 70% did not affect cobas® test perfor-
mance (data not shown).
Discussion
KRAS testing is now mandatory for patients with CRC
being considered for treatment with anti-EGFR monoclonal
antibodies such as cetuximab (Erbitux®, Bristol Myers
Squibb and Merck-Serono) and panitumumab (Vectibix®,
Amgen). Several methods for KRAS testing currently exist,
from commercially available CE-marked test kits to
laboratory-developed tests, but there are limited data to
support the performance of individual methods over others
[21–23]. With the lack of standardization for KRAS testing,
there is a widely recognized need for external quality as-
sessment programs and standards [24, 25]. Indeed, a number
of recent studies have highlighted the variability of mutation
test results from different clinical laboratories [26, 27]. As
results directly affect patient therapy, KRAS tests should be
thoroughly validated on clinically relevant specimen types
(including FFPET) with optimal analytical performance that
encompasses a comprehensive understanding of the impact
of specimen attributes, such as the levels of amplifiable
DNA; the tumor content of FFPET specimens used for
analysis; tissue necrosis; and the influence of endogenous
and exogenous interfering substances.
The cobas® test was thoroughly evaluated with 23
unique performance verification studies and in 188 CRC
clinical specimens. Here, we have reported results on six
of these studies, including methods correlation with Sanger
sequencing, limit of detection, repeatability, interfering sub-
stances, cross-reactivity, and necrosis. These verification
tests were performed in FFPET specimens as well as DNA
derived from cell lines and plasmids. Specimen attributes
that were evaluated were: tumor cell content, potential
effects of endogenous and exogenous interfering substances,
cross-reactivity with KRAS silent mutations and KRAS
homologs, and proportion of necrotic tissue in the FFPET
specimen. These analytic performance attributes have not
been published for other KRAS testing methods.
Concordance between the cobas® test and sequencing
(Sanger plus 454) was 99.5% for codon 12/13 and 100%
for codon 61. The cobas® test had a ≥95% correct mutation
call rate across all specimen types with ~5% mutant alleles
at a DNA input of 0.8–6.3ng/PCR, and a 100% correct
mutation call rate across all specimen types for the recom-
mended DNA input of 50 ng per reaction well. The ability of
this assay to detect KRAS mutations at lower DNA inputs
reduces the likelihood that mutations will be missed in poor-
quality FFPETsamples with limited amounts of amplifiable
DNA. Because we did not perform a systematic assess-
ment of samples with <5% mutant alleles, the detectability
of lower levels of mutation with this assay is uncertain.
Table 4 Repeatability—cobas®
KRAS mutation test accuracy
by test day, reagent lot, operator,
and instrument
Test
day
Reagent
lot
Run Operator Instrument ID Incorrect
results
Valid
results
Accuracy
(%)
1 1 1 A 1 0 12 100
2 B 2 0 12 100
2 3 A 3 0 12 100
4 B 4 0 12 100
2 1 5 A 3 0 12 100
6 B 2 0 12 100
2 7 A 1 0 12 100
8 B 4 0 12 100
3 1 9 A 1 0 12 100
10 B 2 0 12 100
2 11 A 3 0 12 100
12 B 4 0 12 100
4 1 13 A 3 0 12 100
14 B 2 0 12 100
2 15 A 1 0 12 100
16 B 4 0 12 100
Total 0 192 100
Virchows Arch (2012) 460:141–149 147The cobas® test had a mutation result accuracy of 100% for
all specimens and operators combined in the repeatability
study. Neither endogenous interfering factors (hemoglobin
or triglycerides) nor the presence of exogenous colon-related
microorganisms interfered with the test results. The cobas®
test does not cross-react with KRAS silent mutations or
KRAS homologs from the RAS gene family. The cobas® test
gave 100% correct mutation call in FFPETspecimens with up
to 70% necrosis and ≥95% correct mutation call rate in speci-
mens with low tumor content at ≤50 ng per reaction well.
In contrast to other KRAS testing kits, such as the ther-
ascreen® KRAS test (Qiagen, Manchester, UK), which iden-
tifies seven somatic mutations in codons 12 (six mutations)
and 13 (one mutation), the cobas® test identifies 19 mutations
incodons12,13,and61.Basedondatafromthe Catalogue of
Somatic Mutations in Cancer (COSMIC) database [10], the
additional 12 mutations detected by the cobas test represent
approximately 2% of all KRAS mutations or approximately
1% of all CRC cases. However, recent studies suggest that
codon 61 mutations are more prevalent than reflected in the
COSMIC data [28, 29]. Thus, more comprehensive KRAS
mutation coverage may help to improve the selection of
patientsforthistreatment[15].Theanalyticalstudiespresented
in this paperdemonstrate thatthecobas® KRAS Mutation Test
is a thoroughly validated, robust, and reproducible companion
diagnostic test for the detection of the KRAS mutation in CRC
tumors from patients under consideration for treatment with
anti-EGFR monoclonal antibodies.
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